This segment focuses on the research, development, and commercialization of innovative therapies for various cancers. Puma Biotechnology's primary focus within this segment is on HER2-positive breast cancer and HER2 mutation-positive solid tumors. Research and development activities include clinical trials for drug candidates like neratinib (NERLYNX). The company utilizes small molecule therapeutics and collaborates with other companies for distribution and research. The patient impact is significant, as these therapies aim to improve outcomes and quality of life for cancer patients. Market positioning is centered on providing targeted therapies with the potential for improved efficacy and reduced side effects. Future opportunities include expanding the use of existing therapies and developing new treatments for other cancer types. Regulatory and clinical aspects involve obtaining FDA and EMA approvals and conducting clinical trials to demonstrate safety and efficacy. Partnerships and collaborations are crucial for research, development, and commercialization, as seen with agreements with companies like Pierre Fabre and Er-Kim.